What community activism can achieve – ITPC’s 2017 Annual Review
ITPC is proud to share its 2017 Annual Review, titled What Community Activism Can Achieve. The report highlights our successes, challenges, and...
When will ViiV, Clinton Health and partners officially repair the mistake on missing out 39 countries from the DTG pricing agreement?
It has been six months since we alerted the Clinton Health Access Initiative (CHAI) to a glaring omission in the...
Five years after the Indian Supreme Court’s Novartis verdict
Five years after this landmark decision, the impact is being felt around the world. India’s decision is frequently held up...
Patent backlogs fuel efforts to extend pharma patent terms in Thailand and Brazil, AIDS activists say
Excessive patenting in the multinational pharmaceutical sector, along with a huge backlog, works in Big Pharma’s favour. Civil society is...
Groups target EU-Mercosur FTA to advance access to health in trade deals
AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of...
Collective efforts by civil society groups bar the way to Hepatitis C patents
Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
UNAIDS “4th 90”: Affordability of Medicines
UNAIDS has seen Argentina’s proposal to add a 4th “90” to its 90-90-90 strategy as a model to be implemented...